Ros increases BM-derived EPCs in neovascularization.

<p>BM MNCs isolated from Tie2/LacZ mice were used to transplant lethally irradiated syngeneic FVB/NJ mice. One month later, HLI was induced in the recipient mice, and Ros (0.1 mg/kg) was <i>s.c.</i> injected daily. (<b>A–C</b>) At day 14 after HLI, mice were injected with BS lectin and 10 min later, euthanized. The ischemic tissues were stained immunofluorescently with BS lectin (FITC, green) and β-gal (PE, red) to indicate vasculature and BM-derived cells, respectively. (<b>A</b>) Representative images of immunofluorescent double staining. White arrows indicate BS lectin and β-gal double positive cells. 400× original magnification. (<b>B</b>) Quantification of BM-derived EPCs incorporated in the neovasculature (i.e., double positive cells) in the ischemic limb. (<b>C</b>) Quantification of capillary densities (BS lectin-FITC positive cells). n = 6, *P<0.05, **P<0.01 vs. Saline. (<b>D</b>) Blood flow was monitored with LDPI at days 3, 5, 7, 10, 14, and 16 following HLI. *P<0.05, **P<0.01 vs. Saline.